The high cost of cancer drugs and what we can do about it

Mayo Clinic Proceedings

Volumn 87, Issue 10, 2012, Pages 935-943

  Siddiqui, Mustaqeem ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; DASATINIB; DOXORUBICIN; GENERIC DRUG; IMATINIB; IPILIMUMAB; LENALIDOMIDE; NILOTINIB; OFATUMUMAB; PACLITAXEL; SIPULEUCEL T; THALIDOMIDE;

ANTIBIOTIC THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL RESEARCH; COLON CANCER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG USE; EUROPEAN UNION; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH INSURANCE; HODGKIN DISEASE; HUMAN; KIDNEY DISEASE; LICENSING; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; MELANOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NOTE; OFF LABEL DRUG USE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT INDICATION; UNITED STATES; ARTICLE; ECONOMICS; MEDICAL TECHNOLOGY; NEOPLASM; ONCOLOGY; PHARMACOEPIDEMIOLOGY; STATISTICS;

ANTINEOPLASTIC AGENTS; BIOMEDICAL TECHNOLOGY; DRUG COSTS; DRUG UTILIZATION REVIEW; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PHARMACOEPIDEMIOLOGY; PHARMACOVIGILANCE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871874725     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.07.007     Document Type: Short Survey

References (45)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
3. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25(2):180-186.
4. Leveque D. Off-label use of anticancer drugs. Lancet Oncol. 2008;9(11):1102-1107.
5. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 87(10):982-990.
6. Smith K, Jacobson G, Huang J, Neuman T. Projecting Income and Assets: What Might the Future Hold for the Next Generation of Medicare Beneficiaries? Menlo Park, CA: The Henry J. Kaiser Family Foundation; June 2011.
7. Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122(8):741-746.
8. Himmelstein DU, Thorne D, Woolhandler S. Medical bankruptcy in Massachusetts: has health reform made a difference? Am J Med. 2011;124(3):224-228.
9. McKee AE, Farrell AT, Pazdur R, Woodcock J. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist. 2010;15(suppl 1):13-18.
10. Kaitin KI. The landscape for pharmaceutical innovation: drivers of cost-effective clinical research. Pharm Outsourcing. 2010; 2010(May):3605.
11. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25(2):209-216.
12. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clinic Pharmacol Ther. 2010;87(3):272-277.
13. Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85(9):824-833.
14. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010;85(1):77-86.
15. Yoon HH, Khan M, Shi Q, et al. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a Mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010;85(12):1080-1089.
16. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095-1110.
17. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114-122.
18. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc. 2009;84(6):533-545.
19. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319-1331.
20. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626-633.
21. Simpson RJ Jr, Signorovitch J, Birnbaum H, et al. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc. 2009;84(12):1065-1072.
22. Culler SD, Weintraub WS. Is initiation of atorvastatin for employees a good buy for employers? Mayo Clin Proc. 2009; 84(12):1059-1061.
23. Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc. 2009;84(8):675-684.
24. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009;84(2):161-169.
25. Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365(18):1653-1655.
26. Jacobson M, O'Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood). 2006; 25(2):437-443.
27. Jacobson M, Earle CC, Price M, Newhouse JP. How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood). 2010;29(7):1391- 1399.
28. Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008;112(10):2195-2201.
29. The Patient Protection and Affordable Care Act. PL 111-148. March 23, 2010.
30. Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract. 2011;7(3 suppl): e30s-e37s.
31. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010;303(16):1625-1631.
32. AMNOG (Arzneimittelmarktneuordnungsgesetz): law on realignment of the pharmaceutical market in Germany. http://www.articlesbase.com/vision-articles/ amnogarzneimittelmarktneuordnungsgesetz- law-on-realignmentof- the-pharmaceutical-market-in-germany-4119156.html. Accessed June 6, 2012.
33. AMNOG one year on: how will German health reform impact pharma market access in 2012? http://healthcare.blogs.ihs.com/ 2012/02/02/amnog-german-health- reform-pharma-marketaccess- 2012/. Accessed June 6, 2012.
34. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21(5):402-408.
35. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
36. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988;23(2):203-235.
37. Erickson P, Wilson R, Shannon I. Years of healthy life. Healthy People 2000 Stat Notes. 1995;Apr(7):1-15.
38. Fraser J, Steele N, Al Zaman A, Yule A. Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. Eur J Cancer. 2011;47(2):215-220.
39. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80-87.
40. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276(14):1172-1177.
41. Neumann PJ. Emerging lessons from the Drug Effectiveness Review Project. Health Aff (Millwood). 2006;25(4):W262- W271.
42. Gellad WF, Schneeweiss S, Brawarsky P, Lipsitz S, Haas JS. What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings. J Gen Intern Med. 2008;23(9):1435-1440.
43. OECD (2012). OECD Health Data 2012. http://www.oecd. org/health/ healthpoliciesanddata/oecdhealthdata2012- frequentlyrequesteddata.htm. Accessed June 7, 2012.
44. Learn PA, Bach PB. Pem and the cost of multicycle maintenance. J Thorac Oncol. 2010;5(8):1111-1112.
45. de Souza JA, Polite BN, Zhu S, et al. Utilization and costs of non-evidence-based (non-EBM) antineoplastic agents in patients with metastatic colon cancer (mCC). ASCO Meeting Abstracts. 2011;29:6002.